Clinical trials: Mosquito-Borne Diseases
Malaria
Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia
Reactive and proactive case detection measures are widely implemented by national malaria elimination programs globally. Similarly, the Ethiopian Federal Ministry of Health decided to include reactive case detection (RCD) and…
- Trial name
- NCT04241705
- Testing
- Treatment of positive individuals per national treatment guidelines, Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ), Optimized malaria control interventions
- Where
- 10 sites in Ethiopia
- Volunteers
- 48,960 people
- Sponsor
- Armauer Hansen Research Institute, Ethiopia
Malaria, Malaria, Vivax
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax Malaria
- Trial name
- ACTQ (NCT05788094)
- Testing
- Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
- Where
- Thailand
- Volunteers
- 606 people
- Sponsor
- Shoklo Malaria Research Unit
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)
This is a first time in humans (FTiH) study designed to assess the experimental TDENV-PIV vaccine in a predominantly dengue-primed adult population.
- Trial name
- DPIV-002 (NCT01702857)
- Testing
- Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant, Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant, Phosphate buffered saline
- Where
- Puerto Rico
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar.
- Trial name
- NCT00465257
- Testing
- artesunate + amodiaquine
- Where
- Tanzania
- Volunteers
- 110 people
- Sponsor
- Karolinska University Hospital
Plasmodium Falciparum Malaria
A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates
This study aims to assess the safety and effectiveness of four new candidate malaria vaccines; ChAd63 CS, ChAd63 ME-TRAP, MVA CS \& MVA ME-TRAP.
- Trial name
- VAC045 (NCT01623557)
- Testing
- ChAd63-MVA CS, ChAd63-MVA ME-TRAP, Controlled Human Malaria Infection Administered by Mosquito Bite
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue
Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis
Dengue is the most common viral illness spread by mosquitos. It is important to diagnose dengue to prompt adequate therapy and initiate local mosquito control.
- Trial name
- NCT02435615
- Testing
- SaniSal Oral Fluid Collector
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- University of Miami
Plasmodium Falciparum Infection
A Systems Biology Approach to Malaria Immunity
This is a phase I study that will assess the acquisition of immunity to Pf malaria over the course of 5 sequential Controlled Human Malaria Infections (CHMI) over 2-4 years, in 10 healthy adult participants.
- Trial name
- NCT03014258
- Testing
- NF54 P. falciparum malaria challenge
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Evaluating the Role of Chloroquine for Malaria Elimination
One of the proposed ideas for malaria elimination includes the use of drugs to interrupt malaria transmission by exhausting the human reservoir of infection.
- Trial name
- Cloroquina (NCT02698748)
- Testing
- Chloroquine
- Where
- Mozambique
- Volunteers
- 75 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Dengue
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00375726
- Testing
- rDEN3/4delta30(ME)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Malaria, Thrombocytopenia
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
- Trial name
- PLATFORM (NCT05711485)
- Testing
- Whole blood transfusion
- Where
- 2 sites in United States, Zambia
- Volunteers
- 132 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Malaria
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults
The aim of this study is to evaluate the role of azithromycin as a possible combination partner for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium…
- Trial name
- JP011 (NCT01464125)
- Testing
- Fosmidomycin, Azithromycin
- Where
- Thailand
- Volunteers
- 43 people
- Sponsor
- Jomaa Pharma GmbH
Malaria, Malaria, Falciparum
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.
- Trial name
- NCT00408668
- Testing
- PEV3A, FP9 ME-TRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Uncomplicated)
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
This is an ongoing monitoring activity of efficacy of sulfadoxine-pyrimethamine (SP), which is the current national treatment of choice for uncomplicated malaria in Tanzania, and a combination of SP and artesunate among children…
- Trial name
- NCT00140361
- Testing
- Sulfadoxine-pyrimethamine, sulfadoxine-pyrimethamine plus artesunate, lumefantrine plus artemether
- Where
- 3 sites in Tanzania
- Volunteers
- 390 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Pneumonia
Text Message Reminders to Health Workers on Malaria, Pneumonia, and Diarrhea Case Management in Malawi
The purpose of this study is to assess whether twice-daily text message reminders over a six-month period to health workers in Malawi about diagnosis and treatment of malaria, pneumonia, and diarrhea improve case management of…
- Conditions
- Malaria, Pneumonia, Diarrhea
- Trial name
- NCT02645513
- Testing
- Malaria text message reminders to health workers, Malaria, pneumonia, and diarrhea text message reminders to health workers, Control
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Severe Malaria, Malaria
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
This study, conducted by the National Center for Malaria Control of Cambodia's Ministry of Health, the Guangzhou University of Traditional Chinese Medicine in the People's Republic of China, and the U.S.
- Conditions
- Severe Malaria, Malaria, Antimalarial Drug Resistance
- Trial name
- NCT00341003
- Where
- Cambodia
- Volunteers
- 2,090 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Asymptomatic Malaria
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Malaria remains a major cause of illness among school-aged children in sub-Saharan Africa, many of whom carry asymptomatic Plasmodium falciparum infections that may contribute to anemia, inflammation, school absenteeism, and…
- Conditions
- Malaria, Asymptomatic Malaria, Intermittent Preventive Treatment
- Trial name
- Optimal LEAP (NCT07798583)
- Testing
- Monthly DP, Quarterly DP
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Malaria
Community Point Distribution of Insecticide Treated Bed Nets
All households in three zones in Zambia's Eastern Province were invited to attend a community point distribution of insecticide treated bed nets (ITNs).
- Trial name
- NCT02517879
- Testing
- Community point distribution, Community health worker hang-up visit
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- IDinsight
Malaria
Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of spatial repellent products in reducing the incidence of malaria infection in human cohorts.
- Trial name
- SR-M-IDR (NCT02294188)
- Testing
- Spatial Repellent product with active ingredient (SHIELD), Active ingredient, Spatial Repellent product without active ingredient (SHIELD)
- Where
- Indonesia
- Volunteers
- 1,519 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.